Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Douglas Johnson

4 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

VICCMEL0287

05/06/2003

Melanoma, Pigmented Lesion and Cutaneous Malignancy Tissue and Bio-Specimen Repository

Other

VICCMEL12117

02/18/2013

A Multi-Site Retrospective Observational Study of US Patients with Unresectable or Metastatic Melanoma Receiving Ipilimumab (YERVOY?) as First-Line Therapy

Treatment

VICCMEL14106

03/25/2015

A Phase II Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-Drug Conjugate, in Patients with Advanced Melanoma

Treatment

VICCMEL1457

01/19/2015

A Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, to Investigate the Safety and Anti-Cancer Activity in Subjects with Melanoma with BRAF non-V600 Mutations